Breaking News Instant updates and real-time market news.

AFAM

Almost Family

$46.55

0.45 (0.98%)

, CRVS

Corvus Pharmaceuticals

$14.09

0.04 (0.28%)

10:25
01/12/17
01/12
10:25
01/12/17
10:25

JPMorgan to hold a conference

35th Annual Healthcare Conference is being held in San Francisco on January 9-12 with webcasted company presentations to begin on January 12 at 10:30 am; not all company presentations may be webcasted. Webcast Link

AFAM

Almost Family

$46.55

0.45 (0.98%)

CRVS

Corvus Pharmaceuticals

$14.09

0.04 (0.28%)

LMNX

Luminex

$21.19

-0.09 (-0.42%)

VCRA

Vocera

$19.33

-0.38 (-1.93%)

OVAS

OvaScience

$1.61

-0.13 (-7.47%)

DVAX

Dynavax

$4.25

-0.05 (-1.16%)

ARNA

Arena Pharmaceuticals

$1.41

-0.03 (-2.08%)

GEN

Genesis Healthcare

LIFE

aTyr Pharma

$2.35

-0.15 (-6.00%)

NVAX

Novavax

$1.35

-0.08 (-5.59%)

HRTX

Heron Therapeutics

$12.50

-1 (-7.41%)

MGNX

MacroGenics

$19.84

-0.895 (-4.32%)

OMCL

Omnicell

$33.00

0.45 (1.38%)

RTRX

Retrophin

$18.94

-0.68 (-3.47%)

INFY

Infosys

$15.24

0.045 (0.30%)

ITCI

Intra-Cellular

$15.61

-0.945 (-5.71%)

PRTA

Prothena

$49.81

-3.19 (-6.02%)

SGRY

Surgery Partners

$17.95

0.1 (0.56%)

  • 12

    Jan

  • 12

    Jan

  • 23

    Feb

AFAM Almost Family
$46.55

0.45 (0.98%)

10/19/16
RBCM
10/19/16
UPGRADE
Target $55
RBCM
Outperform
Almost Family upgraded to Outperform with $55 target at RBC Capital
RBC Capital analyst Frank Morgan upgraded Almost Family (AFAM) to Outperform from Sector Perform saying the acquisition of Community Health Systems' (CYH) home health care business is a "transformative event" for the company. The deal "significantly" expands Almost Family's geographic footprint while providing a long-term growth opportunity to expand into more of Community Health's markets, Morgan tells investors in a research note. He upped his price target for the shares to $55 from $48.
10/18/16
JEFF
10/18/16
NO CHANGE
Target $58
JEFF
Buy
Almost Family deal highlights low valuation, says Jefferies
Jefferies analyst Brian Tanquilut says Almost Family's (AFAM) acquisition of Community Health's (CYH) home health assets is "very accretive" and not adequately reflected in the shares. The deal further shows Almost Family's low valuation, Tanquilut tells investors in a research note. He believes the stock is "meaningfully undervalued" and keeps a Buy rating on the name with a $58 price target.
11/03/16
BARD
11/03/16
UPGRADE
BARD
Outperform
Almost Family upgraded to Outperform from Neutral at Baird
10/19/16
RBCM
10/19/16
UPGRADE
RBCM
Outperform
Almost Family upgraded to Outperform from Sector Perform at RBC Capital
CRVS Corvus Pharmaceuticals
$14.09

0.04 (0.28%)

04/19/16
BTIG
04/19/16
INITIATION
Target $22
BTIG
Buy
Corvus Pharmaceuticals initiated with a Buy at BTIG
Target $22.
04/18/16
FBCO
04/18/16
INITIATION
Target $25
FBCO
Outperform
Corvus Pharmaceuticals initiated with an Outperform at Credit Suisse
Target $25.
04/18/16
04/18/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Allergan (AGN) initiated with a Neutral at Guggenheim. 2. Clovis (CLVS) initiated with an Outperform at Credit Suisse. 3. Corvus Pharmaceuticals (CRVS) initiated with a Buy at Guggenheim and an Outperform at Cowen and Credit Suisse. 4. Bio-Path Holdings (BPTH) initiated with a Buy at Rodman & Renshaw. 5. Broadcom Limited (AVGO) initiated with an Outperform at Cowen. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/11/16
05/11/16
NO CHANGE

Leerink major pharma & biotech analyst holds analyst/industry conference call
Biotech Analyst Schmidt and Major Pharmaceuticals Analyst Fernandez, along with University of Chicago Departments of Pathology & Medicine, Professor Dr. Thomas F. Gajewski, discuss the tumor micro-environment on an Analyst/Industry conference call to be held on May 11 at 2 pm.
LMNX Luminex
$21.19

-0.09 (-0.42%)

10/12/16
10/12/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AB InBev (BUD) reinstated with an Outperform at Credit Suisse. 2. GrubHub (GRUB) initiated with a Buy at Argus. 3. Dave & Buster's (PLAY) initiated with an Outperform at Wells Fargo. 4. Buckeye Partners (BPL) initiated with a Neutral at Credit Suisse. 5. Luminex (LMNX) initiated with an Outperform at Avondale. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/12/16
AVON
10/12/16
INITIATION
Target $27
AVON
Outperform
Luminex initiated with an Outperform at Avondale
Avondale analyst Sung Ji Nam initiated Luminex with an Outperform and a $27 price target.
05/16/16
PIPR
05/16/16
NO CHANGE
PIPR
Neutral
Piper says Luminex acquired good asset at 'right price' with Nanosphere deal
Piper Jaffray analyst William Quirk said Luminex (LMNX) acquired a good asset with a "solid install base" by agreeing to acquire Nanosphere (NSPH) and that the deal was done "for the right price." However, Luminex will need to finish its pipeline instrument to remain competitive, said Quirk, who keeps a Neutral rating on Luminex shares.
08/18/16
JPMS
08/18/16
UPGRADE
Target $22
JPMS
Neutral
Luminex upgraded to Neutral from Underweight at JPMorgan
JPMorgan analyst Tycho Peterson upgraded Luminex to Neutral saying operational improvements and strong performance of the company's core business make the short thesis less compelling. The analyst raised his price target for the shares to $22 from $18.
VCRA Vocera
$19.33

-0.38 (-1.93%)

07/14/16
07/14/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Ball Corp. (BLL) reinstated with an Equal Weight at Barclays. 2. Southern Company (SO) initiated with a Neutral at Goldman. 3. Achillion (ACHN) initiated with a Sell on lack of data, competition at Chardan. 4. Sallie Mae (SLM) initiated with a Buy at Citi. 5. Vocera (VCRA) initiated with an Outperform at Raymond James. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/08/16
LEER
09/08/16
NO CHANGE
Target $20
LEER
Outperform
Vocera becoming 'attractive acquisition candidate,' says Leerink
Leerink analyst David Larsen is "incrementally more positive" on Vocera after meeting with the company's management. The analyst believes Vocera's new care collaboration suite is opening new doors to larger enterprise deals, and says he expects the company to beat revenue expectations in Q3. Further, Larsen thinks Vocera is becoming an "attractive acquisition candidate." He reiterates an Outperform rating on the stock and raised his price target on the shares to $20 from $18.
01/05/17
CANT
01/05/17
INITIATION
Target $22
CANT
Overweight
Vocera initiated with an Overweight at Cantor
Cantor analyst Steven Halper initiated Vocera with an Overweight and a $22 price target.
01/05/17
LEER
01/05/17
NO CHANGE
LEER
Outperform
Vocera DoD contract positive for long-term outlook, says Leerink
Leerink analyst David Larsen sees Vocera's announced $14M contract with the U.S. Department of Defense for its 23 U.S. Army Medical Command facilities around the world as "a good sign" and positive for long-term outlook. However, the analyst notes this was not entirely new information as the contract was previously disclosed in October with Q3 results. Nonetheless, Larsen says the announcement confirms the entire contract value has now been locked in. He reiterates an Outperform rating on the shares.
OVAS OvaScience
$1.61

-0.13 (-7.47%)

01/25/16
OPCO
01/25/16
DOWNGRADE
OPCO
Perform
OvaScience downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Rohit Vanjani downgraded OvaScience to Perform saying realizing the opportunity for the company's first launched technology, AUGMENT, may take some time. AUGMENT traction may continue to be challenged in 2016, Vanjani tells investors in a research note.
01/21/16
01/21/16
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 3M (MMM) initiated with a Buy at Citi... AMAG Pharmaceuticals (AMAG) initiated with an Equal Weight at Barclays... Acceleron (XLRN) initiated with an Outperform at Credit Suisse... Agios Pharmaceuticals (AGIO) initiated with an Outperform at Credit Suisse... Akebia (AKBA) initiated with a Neutral at Credit Suisse... CIT Group (CIT) initiated with a Hold at Deutsche Bank... Check Point (CHKP) initiated with a Neutral at Cleveland Research... Clovis (CLVS) initiated with an Outperform at Credit Suisse... Colfax (CFX) initiated with a Sell at Citi... Danaher (DHR) initiated with a Neutral at Citi... Dover (DOV) initiated with a Neutral at Citi... Emerson (EMR) initiated with a Sell at Citi... Endo (ENDP) initiated with an Equal Weight at Barclays... Endocyte (ECYT) initiated with an Outperform at Credit Suisse... FibroGen (FGEN) initiated with a Neutral at Credit Suisse... FireEye (FEYE) initiated with an Outperform at Northland... Five Prime (FPRX) initiated with an Outperform at Credit Suisse... Flowserve (FLS) initiated with a Neutral at Citi... General Electric (GE) initiated with a Buy at Citi... Honeywell (HON) initiated with a Buy at Citi... Ignyta (RXDX) initiated with an Outperform at Credit Suisse... Illinois Tool Works (ITW) initiated with a Buy at Citi... Imperva (IMPV) initiated with an Outperform at Northland... Ingersoll-Rand (IR) initiated with a Buy at Citi... Joint Corp. (JYNT) initiated with a Buy at Maxim... M&T Bank (MTB) resumed with a Neutral at JPMorgan... Medivation (MDVN) initiated with an Outperform at Credit Suisse... Newfield Exploration (NFX) initiated with an Outperform at Imperial Capital... OvaScience (OVAS) initiated with an Underperform at Credit Suisse... PFSweb (PFSW) initiated with a Buy at Canaccord... Palo Alto (PANW) initiated with an Outperform at Northland... Perrigo (PRGO) initiated with an Overweight at Barclays... Prothena (PRTA) initiated with an Outperform at Credit Suisse... Puma Biotechnology (PBYI) initiated with an Outperform at Credit Suisse... Rockwell Automation (ROK) initiated with a Neutral at Citi... Seattle Genetics (SGEN) initiated with an Outperform at Credit Suisse... Shopify (SHOP) initiated with an Outperform at Wedbush... Square (SQ) initiated with a Market Perform at William Blair... TESARO (TSRO) initiated with an Outperform at Wedbush... Tyco (TYC) initiated with a Neutral at Citi... Ultragenyx (RARE) initiated with an Outperform at Credit Suisse.
12/07/16
OPCO
12/07/16
INITIATION
OPCO
Perform
OvaScience assumed with a Perform at Oppenheimer
Oppenheimer analyst Derek Archila assumed coverage of OvaScience with a Perform rating citing a lack of revenue visibility.
01/25/16
01/25/16
DOWNGRADE

On The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: American Eagle (AEO) downgraded to Hold from Buy at BB&T... American Express (AXP) downgraded on weak revenue outlook at Argus... Bristol-Myers (BMY) downgraded to Market Perform from Outperform at BMO Capital... Caterpillar (CAT) downgraded to Sell from Neutral at Goldman... Crestwood Equity (CEQP) downgraded to Neutral on potential distribution cut at Baird... Cummins (CMI) downgraded to Neutral from Buy at Citi... Federal Realty (FRT) downgraded to Hold from Buy at Evercore ISI... GKN PLC (GKNLY) downgraded to Neutral from Outperform at Credit Suisse... Galapagos NV (GLPG) downgraded to Neutral from Buy at GoldmanvHortonworks (HDP) downgraded to Perform from Outperform at Oppenheimer... International Flavors (IFF) downgraded on headwinds at Stifel... International Paper (IP) downgraded to Neutral from Buy at Citi... JPMorgan (JPM) downgraded to Neutral from Buy at Nomura... KapStone (KS) downgraded to Underperform from Neutral at Macquarie... Mosaic (MOS) downgraded to Neutral from Overweight at JPMorgan... NetSuite (N) downgraded to Equal Weight from Overweight at Stephens... ONEOK Partners (OKS) downgraded to Neutral at Baird... OvaScience (OVAS) downgraded to Perform from Outperform at Oppenheimer... Packaging Corp. (PKG) downgraded to Neutral from Buy at Citi... Potash (POT) downgraded to Neutral from Overweight at JPMorgan... Power Solutions (PSIX) downgraded to Neutral from Overweight at Piper Jaffray... Raymond James (RJF) downgraded to Neutral from Buy at Nomura... Regeneron (REGN) downgraded to Sell from Neutral at Chardan... SanDisk (SNDK) downgraded to Underperform from Outperform at CLSA... Toll Brothers (TOL) downgraded to Market Perform from Outperform at JMP Securities... Twitter (TWTR) downgraded to Hold from Buy at Stifel... WPX Energy (WPX) downgraded to Sector Perform from Outperform at Iberia... WestRock (WRK) downgraded to Neutral from Buy at BofA/Merrill... Whole Foods (WFM) downgraded to Underperform from Market Perform at BMO Capital... Zurich Insurance (ZURVY) downgraded to Neutral from Outperform at Exane BNP Paribas.
DVAX Dynavax
$4.25

-0.05 (-1.16%)

09/06/16
WBLR
09/06/16
NO CHANGE
WBLR
Outperform
FDA panel cancelation positive for Dynavax, says William Blair
William Blair analyst Y. Katherine Xu views the FDA's decision to canceled the November 16 Vaccines and Related Biological Products Advisory Committee meeting for Heplisav as a net positive for Dynavax. The agency's decision to move straight to the PDUFA date suggests that the Heplisav package is "sufficiently strong and adequate to warrant approval in the absence of a panel," Xu tells investors in a research note. She keeps an Outperform rating on Dynavax. The stock is up 19% to $13.00 in pre-market trading.
11/14/16
COWN
11/14/16
NO CHANGE
Target $45
COWN
Outperform
Dynavax's Heplisav may still have a path forward, says Cowen
Cowen analyst Phil Nadeau called the CRL issued to Dynavax regarding its Biologics License Application for Heplisav-B "disappointing and concerning," but also noted that the FDA did not request new trials. While the CRL will push approval until late 2017, in a best case scenario, there may still be a path forward for approval of the drug, said Nadeau, who added that he thinks the stock now looks undervalued. The analyst has an Outperform rating and $45 price target on Dynavax shares.
11/15/16
WBLR
11/15/16
NO CHANGE
Target $17
WBLR
Outperform
William Blair still sees 'good chance' for approval of Dynavax's Heplisav
William Blair analyst Y. Katherine Xu lowered her price target for Dynavax Technologies to $17 from $45 after the company received a second Complete Response Letter from the FDA for the Heplisav Biologics License Application. There is still a "good chance" for Heplisav to garner eventual approval, Xu tells investors in a research note. The lack of apparent concerns regarding rare serious autoimmune events is a plus, the analyst contends. Xu keeps an Outperform rating on Dynavax. She points out the company's immuno-oncology program SD-101 is reading out substantial data starting in 2017. Dynavax closed yesterday down 65% to $4.10.
04/28/16
RBCM
04/28/16
DOWNGRADE
RBCM
Sector Perform
Dynavax downgraded on drug safety concerns at RBC Capital
As noted earlier, RBC Capital downgraded Dynavax to Sector Perform from Outperform, The firm cited concerns about the safety of the company's Heplisav-B drug as the reason for its downgrade. RBC says that the FDA's decision to request individual trial data instead of the integrated dataset shows that the agency's scrutiny of the drug's safety has increased. Target to $17 from $48.
ARNA Arena Pharmaceuticals
$1.41

-0.03 (-2.08%)

09/15/16
09/15/16
INITIATION
Target $82

Underperform
FBR calls Alexion overvalued, starts shares at Underperform
FBR Capital analyst Christopher James initiated coverage of Alexion Pharmaceuticals (ALXN) with an Underperform rating and $82 price target. The biotech focused on patients with ultra-rare disorders closed yesterday up $2.63 to $129.42. Alexion shares are overpriced as the company is facing a competitive near-term landscape, particularly from Alnylam's (ALNY) ALN-CC5, James tells investors in a research note. Further, near-term expansion into additional indications will be challenging given the recent failed study with eculizumab in refractory generalized myasthenia gravis, the analyst contends. He also sees possible pricing pressures from biosimilars, including an Amgen (AMGN) biosimilar product in development. James this morning also initiated Achillion Pharmaceuticals (ACHN) and Arena Pharmaceuticals (ARNA) with Outperform ratings.
09/15/16
09/15/16
INITIATION
Target $6

Outperform
Arena Pharmaceuticals initiated with an Outperform at FBR Capital
FBR Capital analyst Christopher James started Arena Pharmaceuticals with an Outperform rating and $6 price target.
01/05/17
JMPS
01/05/17
NO CHANGE
JMPS
Market Perform
JMP Securities views Arena amended agreement with Eisai 'favorably'
JMP Securities analyst Jason Butler says Arena Pharmaceuticals' (ARNA) amended agreement with Eisai (ESALY) reduces resource and capital constraints on the company while maintaining "attractive" long-term upside from Belviq success. The analyst notes that Eisai will now have full global development and marketing rights to Belviq in exchange for lowering Arena's royalties and cost contributions, which he views "favorably" as the commercial potential for it remains limited. Furthermore, the new agreement allows Arena to further focus its energies and resources in its Phase 2 pipeline assets, Butler adds. He reiterates a Market Perform on Arena Pharmaceuticals' shares.
03/01/16
PIPR
03/01/16
NO CHANGE
Target $3.5
PIPR
Overweight
Arena Pharmaceuticals price target lowered to $3.50 from $5 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his forecast for Belviq revenue due to Arena in 2016 to $16M from $21.5M after the company reported sales of the weight loss drug were down sequentially in the fourth quarter. The analyst keeps an Overweight rating on Arena shares, noting that data for a Phase II trial of its highest profile pipeline asset, APD334, is now expected in 2017.
GEN Genesis Healthcare

11/21/16
RBCM
11/21/16
DOWNGRADE
RBCM
Sector Perform
Genesis Healthcare downgraded to Sector Perform from Outperform at RBC Capital
11/21/16
RBCM
11/21/16
DOWNGRADE
RBCM
Sector Perform
Genesis downgraded on challenges, divestitures, valuation at RBC Capital
As noted earlier, RBC Capital downgraded Genesis Healthcare to Sector Perform from Outperform. After the company reported slightly weaker than expected Q3 results, analyst Frank Morgan says that industry difficulties are continuing to cause operational challenges for the company. He thinks that these challenges, combined with the company's divestiture from eight states, could "cause bumpiness in its 2017 results." Target to $3.50 from $3.
05/16/16
BOFA
05/16/16
DOWNGRADE
Target $1.8
BOFA
Underperform
Genesis Healthcare downgraded to Underperform from Neutral at BofA/Merrill
BofA/Merrill downgraded Genesis Healthcare to Underperform citing reduced guidance, industry wide pressures, and low debt coverage, among other reasons. The firm cut Genesis' price target to $1.80 from $2.30.
05/16/16
05/16/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Bitauto (BITA) downgraded to Underweight at Morgan Stanley by analyst Amanda Chen, who cited the slowdown in the ad and subscription business, aggressive transaction monetization that could result in dealer push back, and less transparent disclosures. 2. Genesis Healthcare (GEN) downgraded to Underperform at BofA/Merrill citing reduced guidance, industry wide pressures and low debt coverage. 3. Bank of America (BAC) downgraded to Market Perform at Keefe Bruyette by analyst Brian Kleinhanzl, who said the bank has more work to do to improve returns and drive shareholder value higher longer term. 4. UBS (UBS )double downgraded to Underperform at Keefe Bruyette with a price target of CHF 16. 5. Deutsche Bank (DB) downgraded to Sell at Berenberg citing leverage concerns. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
LIFE aTyr Pharma
$2.35

-0.15 (-6.00%)

12/13/16
JPMS
12/13/16
DOWNGRADE
JPMS
Neutral
aTyr Pharma downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Cory Kasimov downgraded aTyr Pharma to Neutral.
04/11/16
BMOC
04/11/16
INITIATION
Target $8
BMOC
Market Perform
aTyr Pharma initiated with a Market Perform at BMO Capital
Target $8.
03/31/16
WBLR
03/31/16
DOWNGRADE
Target $8
WBLR
Market Perform
aTyr Pharma downgraded to Market Perform from Outperform at William Blair
William Blair analyst Y. Katherine Xu downgraded aTyr Pharma to Market Perform and lowered her price target for the shares to $8 from $42 citing the "mixed" Phase Ib/II trial data of Resolaris in adult patients with late-onset facioscapulohumeral muscular dystrophy. ATyr will likely have to conduct a larger, placebo-controlled Phase II trial to explore objective endpoints that could ultimately be used in a pivotal study for approval, Xu tells investors in a research note. This could push approval out to 2021, the analyst contends.
12/13/16
JPMS
12/13/16
DOWNGRADE
JPMS
Neutral
JPMorgan downgrades aTyr Pharma on 'mixed' data
JPMorgan analyst Cory Kasimov downgraded aTyr Pharma to Neutral from Overweight saying the company's Phase 1/2 data for Resolaris from three different studies is a "mixed bag." The data announced today still don't fully define proof-of concept, Kasimov tells investors in a research note. He thinks the company will need time to establish a clear path forward. Kasimov has no target for the shares. aTyr shares are down 80c to $2.85 in afternoon trading.
NVAX Novavax
$1.35

-0.08 (-5.59%)

09/16/16
SBSH
09/16/16
DOWNGRADE
Target $1.5
SBSH
Neutral
Novavax downgraded to Neutral from Buy at Citi
Citi analyst Joel Beatty downgraded Novavax to Neutral after the company's RSV vaccine for older adults failed in Phase 3. The analyst does not expect results from the one remaining clinical trial until 2019. He cut his price target for the shares to $1.50 from $12. Four other firms downgraded Novavax this morning.
12/16/16
CANT
12/16/16
INITIATION
Target $2
CANT
Neutral
Novavax initiated with a Neutral at Cantor
Cantor Fitzgerald analyst William Tanner started Novavax with a Neutral rating and $2 price target.
09/16/16
09/16/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. 21st Century Fox (FOX, FOXA) downgraded to Market Perform from Outperform at Bernstein with analyst Jason Park citing a reduction in his estimates for the company's Star India business. 2. Wells Fargo (WFC) downgraded to Underweight from Neutral at Atlantic Equities. 3. Citi (C) downgraded to Neutral from Buy at Goldman with analyst Richard Ramsden saying Citi's expected earnings inflection has failed to materialize and ROEs are at 7.7%, well below management's 10% target. 4. McCormick (MKC) downgraded to Market Perform from Outperform at Bernstein with analyst Alexia Howard citing valuation. 5. Novavax (NVAX) downgraded to Neutral from Overweight at Piper Jaffray, to Neutral from Overweight at JPMorgan, to Neutral from Buy at Ladenburg, to Neutral from Outperform at Wedbush, and to Neutral from Buy at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/16/16
WEDB
09/16/16
DOWNGRADE
Target $2
WEDB
Neutral
Novavax downgraded to Neutral from Outperform at Wedbush
Wedbush analyst Heather Behanna downgraded Novavax to Neutral and lowered its price target to $2 from $14 after the company's Phase III trial of RSV vaccine failed. This is the fourth downgrade of Novavax today.
HRTX Heron Therapeutics
$12.50

-1 (-7.41%)

01/05/17
JEFF
01/05/17
NO CHANGE
Target $29
JEFF
Buy
Heron Therapeutics price target lowered to $29 from $40 at Jefferies
Jefferies analyst Biren Amin lowered his price target for Heron Therapeutics to $29 after the company guided to 2017 Sustol sales of $15M-$25M, below the consensus of $46M. The outlook conservatively reflects a slow launch which is "largely baked into current prices," Amin tells investors in a research note. The analyst keeps a Buy rating on Heron.
01/05/17
LEER
01/05/17
NO CHANGE
Target $21
LEER
Outperform
Heron Therapeutics price target lowered to $21 from $34 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Heron Therapeutics to $21 from $34 to reflect lower Sustol forecasts and as he now assumes the company will need to raise capital at lower valuations versus his prior assumptions. The analyst notes that Heron Therapeutics provided several clinical and corporate updates which improve his confidence around the HTX-011 program for post-operative pain but diminish his outlook for Sustol in chemo induced nausea and vomiting. He reiterates an Outperform rating on the shares.
11/09/16
COWN
11/09/16
NO CHANGE
Target $40
COWN
Outperform
Heron Therapeutics price target lowered to $40 from $47 at Cowen
Cowen analyst Boris Peaker lowered his price target on Heron Therapeutics (HRTX) to $40 from $47 following the company's Q3 results. The analyst expects a slow sales ramp for Sustol due to competition, reimbursement dynamics, and Tesaro's (TSRO) early experience with its launch of Varubi. Peaker maintained his Outperform rating on Heron Therapeutics shares.
01/05/17
COWN
01/05/17
NO CHANGE
Target $40
COWN
Outperform
Heron Therapeutics weakness a buying opportunity, says Cowen
Cowen analyst Boris Peaker noted Heron Therapeutics released positive Phase 2 abdominoplasty data for HTX-011 but acknowledged the company is a magnet for controversy. The miss on statistical significance at 0-24 hours, as well as Sustol guidance, may create temporary weakness in the shares, said Peaker, who would view the weakness as a buying opportunity. Peaker reiterated his Outperform rating and $40 price target on Heron Therapeutics shares.
MGNX MacroGenics
$19.84

-0.895 (-4.32%)

11/16/16
ROTH
11/16/16
INITIATION
Target $40
ROTH
Buy
MacroGenics reinstated with a Buy at Roth Capital
Roth Capital analyst Mark Breidenbach assumed coverage of MacroGenics with a Buy rating and $40 price target based on a sum-of-parts and the company's pipeline. As the company's lead program progresses in Phase 3 evaluation, Breidenbach believes several catalysts could whet investor appetites in the near term.
09/07/16
COWN
09/07/16
INITIATION
COWN
Outperform
MacroGenics initiated with an Outperform at Cowen
Cowen analyst Boris Peaker initiated MacroGenics with an Outperform rating as he believes its DART bispecific platform is potentially the best in class technology and the company is well capitalized to reach several value creating milestones.
08/04/16
SBSH
08/04/16
DOWNGRADE
SBSH
Neutral
MacroGenics downgraded to Neutral from Buy at Citi
12/20/16
RHCO
12/20/16
INITIATION
Target $30
RHCO
Buy
MacroGenics initiated with a Buy at SunTrust
SunTrust analyst Peter Lawson initiated MacroGenics with a Buy and a $30 price target saying its DART technology is well positioned to rival CAR T cell therapy in cancer. Lawson would be a buyer of shares ahead of 2017 catalysts that include Enoblituzumab combo data, Phase 1/2 gastric combo data, Phase 1 DART data.
OMCL Omnicell
$33.00

0.45 (1.38%)

09/08/16
SIDC
09/08/16
DOWNGRADE
SIDC
Neutral
Omnicell downgraded to Neutral from Buy at Sidoti
01/05/17
CANT
01/05/17
INITIATION
Target $40
CANT
Overweight
Omnicell initiated with an Overweight at Cantor
Cantor analyst Steven Halper initiated Omnicell with an Overweight and a $40 price target.
RTRX Retrophin
$18.94

-0.68 (-3.47%)

11/21/16
BMOC
11/21/16
NO CHANGE
BMOC
Retrophin price target raised to $46 from $40 at BMO Capital
BMO Capital analyst Do Kim raised the price target on Retrophin after the company provided data on its Sparsentan treatment that the analyst views as positive. Kim now sees a 55% chance that the drug will be approved, up from 45% previously. The analyst continues to believe that the FDA might not accept proteinuria as an endpoint, but sees "growing evidence for proteinuria as a surrogate to kidney survival." Kim keeps an Outperform rating on the stock.
11/21/16
LEER
11/21/16
NO CHANGE
LEER
Outperform
Retrophin DUET data reintroduces accelerated approval optionality, says Leerink
Leerink analyst Joseph Schwartz says full DUET Phase 2b results for Retrophin's sparsentan in focal segmental glomerulosclerosis presented at the American Society of Nephrology Kidney Week meeting look "very strong" in terms of the ability of the drug to produce modified partial remissions and even some complete remissions during the 8-week double blind period. The analyst believes the "strong data" provides the company with as good an argument as ever to discuss the potential of accelerated approval with the FDA, although he notes that predicting FDA is "tough." He reiterates an Outperform rating on the shares.
11/11/16
LEER
11/11/16
NO CHANGE
LEER
Outperform
Retrophin agreement for RE-024 bodes well for approval in 2019, says Leerink
Leerink analyst Joseph Schwartz says that the trial design for Retrophin's pending Phase 3 trial of RE-024 and the announced agreement with the FDA under the Special Protocol Assessment process for this trial bode well for potential approval in 2019. The analyst believes the company plans to initiate this trial by the end of 2016, with a drug that has shown "great promise" for the treatment of pantothenate kinase-associated neurodegeneration. He reiterates an Outperform rating on the shares.
12/15/16
JMPS
12/15/16
NO CHANGE
JMPS
Experts support quick approval of Retrophin sparsentan, says JMP Securities
JMP Securities analyst Liisa Bayko says the firm's survey of experts who participated in the Phase 2 study of Retrophin's sparsentan in focal segmental glomerulosclerosis "showed strong support for accelerated approval" of the drug. Bayko reiterates a $28 price target and an Outperform rating on the shares of Retrophin.
INFY Infosys
$15.24

0.045 (0.30%)

01/04/17
UBSW
01/04/17
UPGRADE
UBSW
Neutral
Infosys upgraded to Neutral from Sell at UBS
01/06/17
LYON
01/06/17
DOWNGRADE
LYON
Underperform
Infosys downgraded to Underperform from Outperform at CLSA
11/11/16
11/11/16
NO CHANGE

Infosys invests in TidalScale
Infosys has made an investment in TidalScale, a provider of Software-Defined Servers that deliver in-memory performance at any scale, are self-optimizing, use standard hardware, and are compatible with all applications and operating systems. The investment will be completed on or before November 24.
12/01/16
BOFA
12/01/16
DOWNGRADE
BOFA
Neutral
Infosys downgraded to Neutral from Buy at BofA/Merrill
ITCI Intra-Cellular
$15.61

-0.945 (-5.71%)

12/22/16
BTIG
12/22/16
INITIATION
Target $44
BTIG
Buy
Intra-Cellular initiated with a Buy at BTIG
BTIG analyst Robert Hazlett initiated Intra-Cellular with a Buy and a $44 price target.
12/16/16
CANT
12/16/16
INITIATION
Target $32
CANT
Overweight
Intra-Cellular initiated with an Overweight at Cantor
Cantor Fitzgerald analyst William Tanner started Intra-Cellular Therapies with an Overweight rating and $32 price target.
11/01/16
RBCM
11/01/16
NO CHANGE
RBCM
Intra-Cellular risk/reward 'compelling,.' says RBC Capital
RBC Capital analyst Adnan Butt says the Street "has largely written off" Intra-Cellular's ITI-007 drug, but the analyst thinks that the FDA could still allow the company to file an NDA if data on the drug comes back positive. The analyst says that the drug, which treats schizophrenia, is differentiated from its competitors from a safety perspective. He believes that the drug "is approvable," and he says that the stock's risk/reward is "compelling." He keeps a $49 price target and an Outperform rating on the shares.
09/29/16
RBCM
09/29/16
NO CHANGE
RBCM
Intra-Cellular should be bought on weakness, says RBC Capital
After Intra-Cellular's schizophrenia treatment, ITI-007, failed to perform statistically significantly better than placebo in a Phase 3 study, RBC Capital analyst Adnan Butt says that "early signs" suggest that "higher placebo response" was the culprit. The analyst says that ITI-0007 is safer than competing treatments, and Butt thinks that the FDA still may allow an NDA filing, which he believes would provide a catalyst for the stock in 2017. The analyst says that the stock's risk/reward ratio is positive at current levels. He cut his price target on the shares to $49 from $74 but keeps an Outperform rating on the stock.
PRTA Prothena
$49.81

-3.19 (-6.02%)

11/03/16
DBAB
11/03/16
INITIATION
Target $73
DBAB
Buy
Prothena initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Andrew Peters started Prothena with a Buy rating and $73 price target.
11/09/16
RBCM
11/09/16
NO CHANGE
RBCM
Biotech stocks should be bought on post-election decline, says RBC Capital
RBC Capital recommends buying biotech stocks today on weakness. The firm notes that stocks usually rebound after they drop due to political events that don't affect their fundamentals, and it believes that the decline in biotech stocks today is in that category. The firm says that President-elect Trump probably won't focus on drug prices or Medicare reform. It adds that biotech companies should benefit from the fact that Congress will stay in GOP hands and the apparent failure of California's Proposition 61 initiative. The firm identifies Celgene (CELG), Biogen (BIIB), Vertex (VRTX), BioMarin (BMRN), and Prothena (PRTA) as its favorite names in the sector.
12/20/16
RHCO
12/20/16
INITIATION
Target $75
RHCO
Buy
Prothena initiated with a Buy at SunTrust
SunTrust initiated Prothena with a Buy and a $75 price target.
12/20/16
RHCO
12/20/16
INITIATION
Target $75
RHCO
Buy
Prothena initiated with a Buy at SunTrust
SunTrust initiated Prothena with a Buy and a $75 price target.
SGRY Surgery Partners
$17.95

0.1 (0.56%)

07/13/16
LEHM
07/13/16
INITIATION
Target $20
LEHM
Equal Weight
Surgery Partners initiated with an Equal Weight at Barclays
Barclays analyst Joshua Raskin started Surgery Partners with an Equal Weight rating and $20 price target.
06/10/16
KEYB
06/10/16
INITIATION
KEYB
Overweight
Surgery Partners initiated with an Overweight at KeyBanc
KeyBanc analyst Jason Gurda initiated Surgery Partners with an Overweight and $21 price target. Gurda views shares as attractive given mid-to-high teens EBITDA-NCI growth over the next 3-5 years through organic growth and small acquisitions; its ancillary service development strategy is driving industry leading same facility revenue growth and attractive returns on capital; and valuation.

TODAY'S FREE FLY STORIES

XLE

Energy Select Sector SPDR

$69.57

0.29 (0.42%)

09:54
12/11/17
12/11
09:54
12/11/17
09:54
Technical Analysis
Technical View: Energy Select Sector SPDR leads on the upside »

The Energy Select Sector…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKE

Nike

$61.50

0.195 (0.32%)

09:51
12/11/17
12/11
09:51
12/11/17
09:51
Upgrade
Nike rating change  »

Follow-up: Nike upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Dec

IBB

iShares Nasdaq Biotechnology Index

$106.07

2.02 (1.94%)

09:50
12/11/17
12/11
09:50
12/11/17
09:50
Technical Analysis
Technical View: iShares Nasdaq Biotechnology Index breaks out »

The iShares Nasdaq…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKS

AK Steel

$5.46

0.13 (2.44%)

09:50
12/11/17
12/11
09:50
12/11/17
09:50
Options
Interest in AK Steel Mar 7 calls continues »

Interest in AK Steel Mar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCE

Spark Therapeutics

$73.38

2.82 (4.00%)

09:48
12/11/17
12/11
09:48
12/11/17
09:48
Conference/Events
Spark Therapeutics to hold a pharmaceutical update conference call »

Management reviews the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 12

    Jan

NKE

Nike

$61.67

0.365 (0.60%)

09:47
12/11/17
12/11
09:47
12/11/17
09:47
Upgrade
Nike rating change  »

Nike upgraded to Positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Dec

09:45
12/11/17
12/11
09:45
12/11/17
09:45
General news
JOLTS Job Openings to be reported at 10:00 »

October JOLTS Job…

IOTS

Adesto Technologies

$7.00

-0.45 (-6.04%)

09:44
12/11/17
12/11
09:44
12/11/17
09:44
Conference/Events
Adesto Technologies management to meet with Roth Capital »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 14

    Dec

AGIO

Agios Pharmaceuticals

$60.97

0.14 (0.23%)

09:42
12/11/17
12/11
09:42
12/11/17
09:42
Conference/Events
Agios Pharmaceuticals to hold an investor meeting »

Investor Meeting where…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

KMB

Kimberly-Clark

09:41
12/11/17
12/11
09:41
12/11/17
09:41
Technical Analysis
Technical View: Kimberly-Clark falls in early trading, analyst action »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKS

AK Steel

, CELG

Celgene

$106.09

3.36 (3.27%)

09:40
12/11/17
12/11
09:40
12/11/17
09:40
Options
Unusually active option classes on open December 11th »

Unusual total active…

AKS

AK Steel

CELG

Celgene

$106.09

3.36 (3.27%)

GME

GameStop

CTL

CenturyLink

X

U.S. Steel

ORCL

Oracle

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 18

    Jan

  • 25

    Mar

09:40
12/11/17
12/11
09:40
12/11/17
09:40
General news
Fed funds futures are flat to lower ahead of Wednesday's FOMC »

Fed funds futures are…

ECR

Eclipse Resources

09:35
12/11/17
12/11
09:35
12/11/17
09:35
Conference/Events
Eclipse Resources to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTE

Baytex Energy

09:35
12/11/17
12/11
09:35
12/11/17
09:35
Downgrade
Baytex Energy rating change  »

Baytex Energy downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNN

Smith & Nephew

09:33
12/11/17
12/11
09:33
12/11/17
09:33
Downgrade
Smith & Nephew rating change  »

Smith & Nephew…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YPF

YPF

09:32
12/11/17
12/11
09:32
12/11/17
09:32
Upgrade
YPF rating change  »

YPF upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMS

Fresenius Medical

09:32
12/11/17
12/11
09:32
12/11/17
09:32
Downgrade
Fresenius Medical rating change  »

Fresenius Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEF

Telefonica

09:31
12/11/17
12/11
09:31
12/11/17
09:31
Downgrade
Telefonica rating change  »

Telefonica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEX

IDEX Corp.

09:31
12/11/17
12/11
09:31
12/11/17
09:31
Hot Stocks
IDEX Corp. announces acquisition of thinXXS Microtechnology AG »

IDEX Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HD

Home Depot

09:31
12/11/17
12/11
09:31
12/11/17
09:31
Downgrade
Home Depot rating change  »

Home Depot downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

AIBSF

Allied Irish Banks

09:29
12/11/17
12/11
09:29
12/11/17
09:29
Downgrade
Allied Irish Banks rating change  »

Allied Irish Banks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARGX

Argenx

$30.45

0.05 (0.16%)

09:29
12/11/17
12/11
09:29
12/11/17
09:29
Conference/Events
Argenx to hold a workshop »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

VTGN

VistaGen Therapeutics

$1.80

-0.23 (-11.33%)

09:27
12/11/17
12/11
09:27
12/11/17
09:27
Syndicate
VistaGen Therapeutics announces pricing of common stock and warrant offering »

VistaGen announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIT

Fitbit

, CBOE

CBOE Holdings

$125.27

1.08 (0.87%)

09:26
12/11/17
12/11
09:26
12/11/17
09:26
Hot Stocks
On The Fly: Pre-market Movers »

HIGHER: Fitbit (FIT), up…

FIT

Fitbit

CBOE

CBOE Holdings

$125.27

1.08 (0.87%)

NXPI

NXP Semiconductors

$115.29

0.16 (0.14%)

QURE

uniQure

$17.82

0.8 (4.70%)

CSIQ

Canadian Solar

$17.25

0.13 (0.76%)

PZRX

PhaseRx

$1.00

0.0126 (1.28%)

WPC

W.P. Carey

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

NDAQ

Nasdaq

$78.78

0.99 (1.27%)

09:26
12/11/17
12/11
09:26
12/11/17
09:26
Recommendations
Nasdaq analyst commentary  »

Nasdaq price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.